Research Topics
Species | M LadettoSummaryAffiliation: University of Turin Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patientsM Ladetto
Divisione Universitaria di Ematologia Azienda Opedaliera S Giovanni Battista Torino, Italy
Med Oncol 17:203-10. 2000....- High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicityC Tarella
Dipartimento di Medicina e Oncologia Sperimentale, Ospedaliera S Giovanni Battista di Torino, Italy
Leukemia 15:256-63. 2001..It implies good tolerability and reversible cardiotoxicity and it may have contributed to the good long-term outcome observed in this series of patients... 
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survivaMarco Ladetto
Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
Blood 111:4004-13. 2008..This trial was registered at www.clinicaltrials.gov as no. NCT00435955...
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero
Division of Hematology, Department of Experimental Medicine and Oncology, University of Turin, Italy
Haematologica 97:849-53. 2012..Early B-lymphocyte precursors of multiple myeloma are known to exist and might be susceptible to antigenic drive...- Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto
Dipartimento di Medicina ed Oncologia Sperimentale, Servizio di Epidemiologia dei Tumori e Biostatistica, Centro di Ricerca in Medicina Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
Blood 105:4784-91. 2005..Future studies will assess COX-2 involvement in other hematologic tumors and its potential use as a therapeutic or chemo-preventive target in onco-hematology... - Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populationsMarco Ladetto
Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino A O San Giovanni Battista della Citta di Torino, Torino, Italy
Exp Hematol 34:1680-6. 2006..To address these issues we prospectively monitored a panel of NLABR-positive LFS... - Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disordersMarco Ladetto
Cattedra di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, 10126 Turin, Italy
Blood 103:4644-9. 2004.... - Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphomaMarco Ladetto
Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, Torino, Italy
Biol Blood Marrow Transplant 12:1270-6. 2006..Our results indicate that rituximab is active against residual MCL cells and suggest that molecularly tailored maintenance therapy needs to be investigated in clinical trials... - Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma cloneMarco Ladetto
Divisione di Ematologia Dipartimento di Medicina ed Oncologia Sperimentale, Universita di Torino, A O San Giovanni Battista della Citta di Torino, Torino, Italy
Exp Hematol 31:784-8. 2003.... - PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto
Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Italy
J Clin Oncol 21:1398-403. 2003.... - High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto
Divisione Universitaria di Ematologia, Cattedra di Ematologia, Ospedale S Giovanni Vecchio antica sede, Torino, Italy
Blood 100:1559-65. 2002.... - Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvestsMarco Ladetto
Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Exp Hematol 30:529-36. 2002..In this study, we used a validated real-time polymerase chain reaction (PCR) strategy to evaluate LTC of BM and PBPC samples obtained from MM patients... - Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autograftingM Ladetto
Divisione Universitaria di Ematologia Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Leuk Lymphoma 40:679-82. 2001..However, the prolonged remission duration observed in this patient suggests that achieving PCR-negativity may also be of benefit for MCL patients... - Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myelomaMarco Ladetto
Cattedra di Ematologia, Via Genova 3, 10126 Torino, Italy
J Clin Oncol 28:2077-84. 2010..Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs... - A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patientsM Ladetto
Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Exp Hematol 29:183-93. 2001..In this study we evaluated whether there is a relationship between tumor burden of stem cell harvests and successful clearance of PCR-detectable disease following ex vivo manipulation... - Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trialM Ladetto
Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
Leukemia 20:1840-7. 2006..As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy... - Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto
Divisione Universitaria di Ematologia-Dipartimento di Medicina ed Oncologia Sperimentale, , Torino, Italy
Leukemia 15:1941-9. 2001..In pre-treated patients this treatment also showed promising results, although the risk of severe infections needs to be considered... - Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSFI Ricca
Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale, , Torino, Italy
Leukemia 19:644-51. 2005.... - Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cellsP Corradini
Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni Battista Divisione Universitaria di Ematologia, Torino, Italy
J Clin Oncol 17:208-15. 1999..To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation of hematopoietic cells... - Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo ItalianC Tarella
Dip Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
Leukemia 21:1802-11. 2007..Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy... - Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsI Ricca
Divisione di Ematologia, Dipartimento di Medicina ed Oncologia Sperimentale Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
Leukemia 21:697-705. 2007..In conclusion, TRF-L can be helpful to refine prognostication of B-CLL patients, particularly those with a VH-unmutated immunoglobulin sequence... - Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere statusM Ruella
Dipartimento di Medicina ed Oncologia Sperimentale, Divisione di Ematologia, Universita di Torino, Torino, Italy
Bone Marrow Transplant 45:505-12. 2010..0005); following HSCT, BM TL (median 7380 bp) was identical to that of the graft (P=NS). We conclude that grafted cells have a major role in determining TL after HSCT... - Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cellsS Lamorte
Department of Internal Medicine, Research Center for Experimental Medicine CeRMS, University of Torino, Torino, Italy
Leukemia 26:1081-90. 2012..These results suggest that syndecan-1 may contribute to the highly angiogenic phenotype of MMECs by promoting EC proliferation, survival and modulating VEGF-VEGFR-2 signalling... - IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cellsM Coscia
Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, Italy
Leukemia 25:828-37. 2011..This vulnerability of UM CLL B cells can be exploited as a selective target of therapeutic interventions... - Clinical significance of cyclooxygenase-2 (COX-2) in multiple myelomaA Trojan
Multidisciplinary Oncology Centre, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland
Swiss Med Wkly 136:400-3. 2006..However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival... - Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantationC Voena
Laboratorio Ematologia Molecolare, Istituto Scientifico HS Raffaele, Milano, Italy
Bone Marrow Transplant 32:791-3. 2003..These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation... - BRAF gene is not mutated in plasma cell leukemia and multiple myelomaL Bonello
Leukemia 17:2238-40. 2003